MIRA
MIRA PHARMACEUTICALS, INC.
$1.00
-5.66%
$42.0M
No data for this timeframe.
Vol
Market Cap$42.0M
Cap SizeNano Cap
Inst. Holders4 funds
Inst. Value$1.0M
Inst. Activity2 buys / 2 sells
SEC Reports3
Recent Activity
Jun 4, 2026
SEC
MIRA Pharmaceuticals entered into an Amended and Restated Exclusive License Agreement with MIRALOGX LLC, securing worldw
8-K — Impact 3/10
May 27, 2026
SEC
MIRA Pharmaceuticals expanded its exclusive license for Ketamir-2 from North America to worldwide rights and added inter
8-K — Impact 5/10
May 13, 2026
SEC
MIRA Pharmaceuticals announced the publication of a peer-reviewed manuscript on its preclinical drug candidate SKNY-1 in
8-K — Impact 3/10
May 12, 2026
earnings_calendar
MIRA Q1 2026 Earnings Scheduled — 2026-05-12
Mar 30, 2026
Insider
Aminov Erez sold 83,500 shares
Chief Executive Officer @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — DOUBLED
660,497 shares ($997.4K)
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
27,044 shares ($40.8K)
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 30, 2024 | Rodman & Renshaw | INITIATE | Buy |
| Aug 5, 2024 | Ascendiant Capital | INITIATE | Buy |
Latest Reports
NEUTRAL
8-K
3/10
MIRA Pharmaceuticals entered into an Amended and Restated Exclusive License Agreement with MIRALOGX LLC, securing worldw
Jun 4, 2026
BULLISH
8-K
5/10
MIRA Pharmaceuticals expanded its exclusive license for Ketamir-2 from North America to worldwide rights and added inter
May 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $997.4K | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $40.8K | TRIM |
| BANK OF AMERICA CORP | $395.00 | ADD |
| WELLS FARGO & COMPANY/MN | $35.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 30, 2026 | Aminov Erez | A | $0.00 |
4 institutional holders with $1.0M total value (687,825 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 660,497 | $997.4K | 96.0% | DOUBLED +224.3% |
| 2 | TWO SIGMA INVESTMENTS, LP | 27,044 | $40.8K | 3.9% | TRIM -40.8% |
| 3 | BANK OF AMERICA CORP /DE/ | 261 | $395.00 | 0.0% | ADD +86.4% |
| 4 | WELLS FARGO & COMPANY/MN | 23 | $35.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | DOUBLED | 203,643 | 660,497 | +224.3% | $997.4K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 45,703 | 27,044 | -40.8% | $40.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 140 | 261 | +86.4% | $395.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 46,700 | 0 | -100.0% | $0.00 | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 117,824 | 203,643 | +72.8% | $277.0K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 46,700 | — | $63.5K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 19,887 | 45,703 | +129.8% | $62.2K | 2025-Q3 |
| UBS Group AG | TRIM | 500 | 216 | -56.8% | $294.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 10,103 | 119 | -98.8% | $144.00 | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 45,772 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 97,976 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 97,976 | — | $111.7K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 45,772 | — | $52.2K | 2024-Q4 |
1 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 30, 2026 | Aminov Erez | Chief Executive Officer | A | 83,500 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 3.7/10.
NEUTRAL
8-K
3/10
MIRA Pharmaceuticals entered into an Amended and Restated Exclusive License Agreement with MIRALOGX
Jun 4, 2026
BULLISH
8-K
5/10
MIRA Pharmaceuticals expanded its exclusive license for Ketamir-2 from North America to worldwide ri
May 27, 2026
NEUTRAL
8-K
3/10
MIRA Pharmaceuticals announced the publication of a peer-reviewed manuscript on its preclinical drug
May 13, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Sep 2024): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 30, 2024 | Rodman & Renshaw | INITIATE | — | Buy |
| Aug 5, 2024 | Ascendiant Capital | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings_calendar
MIRA Q1 2026 Earnings Scheduled — 2026-05-12
Apr 1, 2026
short_volume
Short Volume: MIRA — 58.2% short (0.3M / 0.5M)
Short: 305,323 | Exempt: 9,600 | TRF Vol: 524,621 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)